Noribogaine (also called 12-hydroxyibogamine) is the primary metabolite of ibogaine — the compound ibogaine becomes after it is metabolised by the liver, primarily via the CYP2D6 enzyme. It has distinct pharmacological properties from ibogaine itself: a longer half-life, stronger SERT inhibition, kappa-opioid receptor activity, and the capacity to upregulate GDNF in the brain. While ibogaine produces the 12–24 hour active ceremony experience, noribogaine is what remains biologically active in the body for weeks to months after ceremony ends.

How long does noribogaine stay in the body after ibogaine ceremony?

After a flood dose ceremony, noribogaine remains biologically active for weeks to months. Its half-life is substantially longer than ibogaine's — which clears in hours — and its pharmacological effects persist across the integration period. This is clinically significant because the contraindications related to serotonergic medications (SSRIs, SNRIs, MAOIs) remain in effect throughout the period when noribogaine is active, not just during the ceremony itself.

Does noribogaine produce the visionary effects of ibogaine ceremony?

No. The visionary and confrontational qualities of the ibogaine experience are driven primarily by ibogaine itself. Noribogaine does not cross the blood–brain barrier as readily as ibogaine, which is why it does not replicate the acute experience. What it does instead is sustain the neuroplasticity window: maintaining GDNF upregulation, kappa-opioid receptor modulation, and SERT inhibition for weeks after the acute experience has ended.

Why are SSRIs and SNRIs still contraindicated after ibogaine ceremony ends?

Noribogaine is a potent serotonin transporter (SERT) inhibitor — the same target as SSRIs. When noribogaine is present and an SSRI is added, serotonin levels in the synapse can reach dangerous concentrations, producing serotonin syndrome — a potentially fatal condition. This risk does not end when the ibogaine ceremony ends. Any restart of SSRIs or SNRIs after ceremony requires explicit coordination with a physician who understands the noribogaine timeline. Do not rush the restart to manage the low mood or anxiety that sometimes follows ceremony.

What is the integration window and how long does it last?

The integration window is the period of elevated neuroplasticity that follows ibogaine ceremony — sustained in significant part by noribogaine's continued activity and GDNF upregulation in the brain. During this window, the brain is more receptive to new patterns of thought, response, and behaviour, and the craving reduction initiated by ibogaine is maintained. The window is weeks to months, not years. What is done during it — changes to environment, relationships, and patterns; structured integration coaching — determines whether the confrontation the ceremony produced translates into lasting change.

Who should not proceed with ibogaine ceremony?

Absolute medical contraindications: QT prolongation or significant cardiac arrhythmia on baseline EKG; recent myocardial infarction; severe liver or kidney disease; active psychosis or schizophrenia-spectrum disorder; lithium; pregnancy. Current SSRIs or SNRIs are an absolute contraindication — physician-supervised taper to completion is required before any ceremony discussion, not dose reduction. Methadone requires a specific multi-month transition protocol. People in acute psychiatric crisis are not appropriate candidates regardless of motivation. People who cannot access or commit to integration support are not strong candidates — the ceremony produces a window; without the conditions to use it, the window closes on unchanged terrain.

What does GDNF have to do with the integration window?

Glial cell line-derived neurotrophic factor (GDNF) is a protein that supports the survival and function of dopaminergic neurons — the neurons most damaged by sustained substance use. Both ibogaine and noribogaine upregulate GDNF in the brain. This upregulation is part of the neurological repair mechanism that makes the post-ceremony period more than simply recovery — it is a period of active neuroplasticity. The 88% reduction in PTSD symptoms and 87% reduction in depression symptoms at one month in the 2023 Stanford Nature Medicine study occurred during the period when both noribogaine and GDNF upregulation were still active.

Can noribogaine be detected on a drug test?

Yes. Noribogaine has a long half-life and can be detected in urine and other biological samples for weeks after a flood dose ceremony. Standard drug panels do not typically screen for ibogaine or noribogaine, but specialised forensic panels can identify them. If a drug test is relevant — for employment, legal, or medical reasons — this timeline should be discussed during the intake process before proceeding.

Noribogaine: The Metabolite That Shapes the Integration Window

Noribogaine is what ibogaine becomes inside the body. When ibogaine is ingested, the liver metabolises it to noribogaine—a compound with its own pharmacological profile, a substantially longer half-life, and a central role in what happens after ceremony ends. The integration window that determines whether ibogaine produces lasting change is, in significant part, a noribogaine window.

This matters because most people who consider ibogaine ceremony focus on the ceremony itself: the 12–24 hours of active experience, the confrontational quality of what it produces, the nausea and light sensitivity. What receives less attention is the weeks and months that follow. Noribogaine is why that period is not simply recovery—it is the window during which the neurological conditions for change remain elevated.

Key facts

Noribogaine is the primary metabolite of ibogaine, produced via CYP2D6 liver enzymes
Half-life is substantially longer than ibogaine's—it remains detectable for weeks to months after a flood dose ceremony
Primary pharmacological actions include SERT inhibition, kappa-opioid receptor activity, and GDNF upregulation
SSRIs and SNRIs remain absolute contraindications during the entire noribogaine window—serotonin syndrome risk does not end when the ceremony does
The 88% reduction in PTSD symptoms in the 2023 Stanford Nature Medicine study was measured at one month—during the period when noribogaine is still active

What noribogaine is

Ibogaine and noribogaine are chemically related but pharmacologically distinct. Ibogaine is the alkaloid that produces the active ceremony experience: the 12–24 hours of confrontational, visionary, and deeply introspective content. Noribogaine is what ibogaine becomes after it passes through the liver. The two compounds share structural similarities but differ in how they interact with receptors, how long they remain active, and what they produce.

The key difference: ibogaine crosses the blood–brain barrier readily. Noribogaine does not cross as readily, which is why it does not replicate the acute visionary experience. What it does instead is persist. Ibogaine's half-life in the body is measured in hours. Noribogaine's half-life is measured in days—and after a flood dose, it remains biologically active for weeks to months.

This metabolic relationship is well-established. The question that research has focused on increasingly is what noribogaine does during that extended window—because the clinical changes attributed to ibogaine treatment do not stop when the acute experience ends.

How ibogaine becomes noribogaine

When ibogaine is absorbed, it undergoes first-pass metabolism in the liver. The primary metabolic pathway is O-demethylation via the CYP2D6 enzyme (and to a lesser extent CYP3A4), which converts ibogaine to noribogaine (also called 12-hydroxyibogamine). This conversion is not incidental—it is the dominant metabolic route.

The practical implication is that after ibogaine ingestion, the body carries both compounds simultaneously. Ibogaine drives the acute experience; noribogaine begins accumulating during and after ceremony and continues to be present long after ibogaine itself has cleared. For participants, this means that what happens after ceremony—not just during it—occurs in a pharmacologically active context.

Individual variation in CYP2D6 activity affects how quickly this conversion occurs and at what levels noribogaine accumulates. This is one of several reasons medical screening and on-site physician oversight are not optional safety measures—they are how individual variation in metabolism gets assessed and monitored.

What noribogaine does in the body

Noribogaine has three pharmacological actions most relevant to its clinical significance:

SERT inhibition.Noribogaine is a potent inhibitor of the serotonin transporter (SERT)—more potent than ibogaine itself in this respect. The serotonin transporter is the target of SSRIs. This is not incidental. It is the mechanism behind the absolute contraindication that SSRIs and SNRIs are not just unsafe before ceremony but during the entire period when noribogaine remains active. Serotonin syndrome—a potentially fatal condition caused by excess serotonergic activity—is a real risk while noribogaine is present. This risk does not end when the ceremony does.

Kappa-opioid receptor activity. Noribogaine acts on kappa-opioid receptors, which modulate craving, reward-related processing, and withdrawal responses. This is part of the mechanism behind the sustained reduction in substance craving observed in the weeks after ceremony. The opioid receptor reset that ibogaine initiates is maintained in part by noribogaine's continued activity at these receptors.

NMDA receptor modulation.Like ibogaine, noribogaine interacts with NMDA receptors. NMDA antagonism is associated with neuroplastic changes—the conditions that make new learning and new patterns of response more possible. The extended noribogaine window maintains a degree of this modulation for weeks after the acute ibogaine experience has ended.

GDNF and the neuroplasticity basis

Both ibogaine and noribogaine have been shown to upregulate glial cell line-derived neurotrophic factor (GDNF) in the brain. GDNF is a protein that supports the survival and development of dopaminergic neurons—the neurons most damaged by sustained substance use. When dopaminergic neurons are functioning properly, the brain's reward system can respond to natural rewards rather than requiring escalating substance use to produce a response.

GDNF upregulation is part of why ibogaine is not simply a temporary interruption of craving. The 2023 Stanford study in Nature Medicine documented average reductions of 88% in PTSD symptoms, 87% in depression symptoms, and 81% in anxiety symptoms at one month in 30 special operations veterans with treatment-resistant conditions. That measurement point—one month post-treatment—is not incidental. It coincides with the period during which noribogaine is still active and GDNF upregulation is still sustained.

The conventional antidepressant research standard considers a 50% reduction in depression scores a “strong response.” The Stanford data, taken at a month when noribogaine was still present, exceeded that threshold by 37 percentage points. The study has genuine limitations—30 participants, no placebo arm—and those caveats should accompany any citation. The numbers stand with the caveats included.

The $50 million USD committed to follow-on ibogaine clinical trials at UTMB, UTHealth Houston, Texas A&M University, and Baylor University reflects how seriously the research community takes these findings. NIDA's opioid research programme provides context for where ibogaine sits within the broader field of substance use disorder treatment.

Why the integration window exists

The ceremony opens something. The question is what happens while it is open.

Noribogaine's extended presence sustains a period of elevated neuroplasticity—a window during which the brain is more receptive to new patterns of thought, response, and behaviour. This is not an indefinite state. The window does not stay open permanently. What is done during it determines whether the confrontation the ceremony produced translates into lasting change.

The pattern that closes the window early is consistent. The ceremony was profound. The person left with clarity, reduced craving, what felt like the beginning of something different. Six weeks later, they were back where they started—or worse, because the contrast between what had seemed possible and what they returned to was now sharper. This happens when people return immediately to the same environment, relationships, and unaddressed conditions that produced the problem. The ceremony opened a window. The window does not stay open indefinitely. What is done in that window determines the outcome.

Integration coaching—$150–$300 CAD per session (60–90 minutes)—is not an optional add-on. It is the work done during the window that noribogaine sustains. Providers who hand participants a pamphlet and wish them luck are not providing ibogaine treatment—they are providing ibogaine. The difference matters. The integration period is where outcomes are determined, not where they are simply observed.

Drug interactions: the window extends further than expected

One of the most underestimated aspects of ibogaine ceremony is how long the contraindications persist afterward. Most people understand that SSRIs and SNRIs are absolutely contraindicated before ceremony—a physician-supervised taper to completion is required before any ceremony discussion, not a dose reduction, not informal cessation. What receives less attention is that those contraindications do not end when the ceremony does.

Noribogaine's SERT inhibition means that reintroducing serotonergic medications while noribogaine is active carries the same serotonin syndrome risk as taking them before ceremony. The window for this risk is not 24 hours. It is weeks—the duration of noribogaine's biological activity.

Any restart of serotonergic medications after ibogaine ceremony requires explicit communication with a physician who understands this timeline. The pre-ceremony SSRI taper timeline is well-documented; the post-ceremony restart window requires the same level of attention. Rushing the restart to manage anxiety or low mood in the integration period is a risk that the pre-ceremony preparation process should address directly.

Other medications requiring specific monitoring during the noribogaine window: lithium (absolute contraindication that continues after ceremony), MAOIs (the interaction risk with noribogaine's SERT inhibition is real), and any medication with cardiac effects, since noribogaine retains some of ibogaine's cardiac activity. The post-ceremony period is not a pharmacologically neutral period.

Who Is Not Right for This Work

The contraindications are not bureaucracy. They exist because ibogaine and noribogaine are pharmacologically active compounds with real cardiac and serotonergic risks, and those risks apply throughout the extended window, not just during the ceremony itself.

Absolute medical contraindications: QT prolongation or significant cardiac arrhythmia on a baseline EKG; recent myocardial infarction; severe liver or kidney disease; active psychosis or schizophrenia-spectrum disorder; lithium; pregnancy. Current SSRIs or SNRIs require a physician-supervised taper to completion before any ceremony discussion—not dose reduction, not informal cessation. Methadone requires a specific clinical transition protocol that typically takes several months.

Someone in acute psychiatric crisis is not an appropriate candidate, regardless of motivation or urgency. The experience amplifies what is present. Entering it in a state of acute instability does not produce stability.

Someone who cannot access or engage with integration support is not a strong candidate. The ceremony produces an opening. Without the conditions to do something with it—a commitment to change the environment and patterns that produced the problem; structured integration coaching; time and space from the original triggers—the noribogaine window closes on unused terrain.

Is This Right for You?

Understanding noribogaine is relevant not because the metabolite needs to be managed intellectually, but because the integration period is where outcomes are actually determined. The ceremony is 12–24 hours. The noribogaine window is weeks to months. The two are not the same thing.

The ceremony page describes what the active experience involves. The integration page covers what the weeks and months following ceremony require and what integration coaching supports during that period. The FAQ covers the most common questions about screening and what the process involves.

If you are not a candidate—a confirmed cardiac contraindication, a current medication that requires a supervised taper, a state of acute crisis—you will be told that directly. That is the most useful thing the intake process can do for someone who is not yet in a position to proceed. Applications are open, and every one receives a genuine response within 2–3 business days.